text_1: Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.
text_2: Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.